`Preliminary Amendment
`
`Attorney Docket No. 46682-7013 19
`
`SMENDMENTS TO THE CLAIMS
`
`This listing of claims replaces all prior versions and listing of claims in the above-
`
`referenced patent application. The following amendments do not constitute an admission
`
`regarding the patentability of the amended subject matter and should not be so construed,
`
`Amendments to the claims were made for purposes of more clearly stating the claimed subject
`
`matter and do not add new matter or alter the scope of the claims. Deletions are denoted by
`
`[strikethrough] and additions are denoted by underline.
`
`Listing of the Claims
`
`31.-48. (Canceled)
`
`49, (New) An ophthalmic composition, comprising about 0.001 %w/vto about 0.05 % w/v
`
`atropine; sodium chloride; glycerin; chitosan; povidone; and water, at a pH of from about
`
`3.8 to about 7.5.
`
`50. (New) The ophthalmic composition of claim 49, comprising about 0.025 %w/vatropine.
`
`Si. (New) The ophthalmic composition of claim 49, comprising about 0.01 %w/watropine.
`
`mnfed. (New) The ophthalmic composition of claim 49, comprising about 0.05 %w/vatropine.
`
`CFsGs. (New) The ophthalmic composition of claim 49, further comprising edetate disodium,
`
`an bin,. (New) The ophthalmic composition of claim 49, wherein the ophthalmic composition has a
`
`pHof about 5.5.
`
`on OR. (New) The ophthalmic composition of clair 49, wherein the composition has a dose-to-
`
`dose ophthalmic concentration variation of less than 40%,
`
`et aN. (New) The ophthalmic composition of claim 49, wherein the ophthalmic composition
`
`coniprises at least about 80% of the atropine based on initial concentration after extended
`
`period of time under storage condition.
`
`57. (New) The ophthalmic composition of claim 56, wherein the ophthalmic composition
`
`further bas a potency of one of: at least 80%after extended period of time under storage
`
`condition.
`
`58. (New) The ophthalmic composition of claim 56, wherein the storage condition has a
`
`storage temperature of from about 2°C to about 10°C or from about 16°C to about 26°C.
`
`
`
`US. Serial No. 17/721.831
`Preliminary Amendment
`
`Attorney Docket No. 46682-7013 19
`
`39,
`
`(New) A method oftreating myopia, comprising administering an ophthalmic composition
`
`to a subject in need thereof, wherein the ophthalmic composition comprises: about 0.001 %
`
`wiv to about 0.05 %w/v atropine; sodiumchloride; glycerin, chitosan, povidone; and
`
`water, at a pH of from about 3.8 to about 7.5.
`
`. (New) The method of claim 59, comprising about 0.025 % w/vatropine.
`
`. (New} The method of claim 59, comprising about 0.01 %w/vatropine.
`
`. (New) The method of claim 59, comprising about 0.05 %w/vatropine.
`
`. (New} The method of claim 59, further comprising edetate disodium.
`
`. (New} The method of claim 59, wherein the ophthalmic cornposttion has a pH of about 5.5.
`
`. (New} The method of claim 59, wherein the composition has a dose-to-dose ophthalmic
`
`concentration variation of less than 40%.
`
`66.
`
`(New) The method of claim 59, wherein the ophthalmic composition comprises at least
`
`about 80% of the atropine based on initial concentration after extended period of time
`
`under storage condition.
`
`67,
`
`(New) The method of claim 66, wherein the ophthalmic composition further has a potency
`
`of one of: at least 80%after extended period oftime under storage condition.
`
`63.
`
`(New} The method of claim 66, wherein the storage condition has a storage temperature of
`
`from about 2°Cto about [O°C or from about 16°C to about 26°C.
`
`3
`
`